secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2023-07-25T23:59:59+00:00
Accession:  0001104659-23-083629
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa Q2 ARCALYST revenue $54.5M; raises FY2023 guidance to $220-230M
-----------------------------------------------------------------------

- Q2 total revenue $71.5M (vs $27.0M YoY), ARCALYST net product revenue $54.5M (vs $27.0M YoY).
- Net income $15.0M vs net loss $20.0M YoY; includes $16.2M tax benefit from valuation allowance release.
- 2023 ARCALYST revenue guidance raised to $220-230M from $200-215M; cash runway extended into at least 2027.
- Over 1,250 prescribers have written ARCALYST; average therapy duration ~20 months; 45% of patients restarted within 8 weeks.
- KPL-404 Phase 2 rheumatoid arthritis data expected in 1H 2024; $15.0M milestone from Genentech vixarelimab agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465923083629/0001104659-23-083629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465923083629/tm2321659d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-083629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer